Walgreens strikes $683 million opioid deal with Florida

  • Walgreens Boots Boots Alliance (NASDAQ:WBA) has agreed to pay $683 million to settle claims that the company contributed to the opioid crisis in the state by improperly dispensing millions of painkillers, as per state officials.
  • The deal includes a one-time payment of $63 million for attorney's fees and $620 million to be paid out to the state over 18 years.
  • 'I am glad that we have been able to end this monumental litigation and move past the courtroom," Florida Attorney General Ashley Moody said.
  • In a statement, Deerfield, Illinois-based Walgreens Boots (WBA) did not admit wrongdoing. 'As the largest pharmacy chain in the state, we remain focused on and committed to being part of the solution, and believe this resolution is in the best interest of all parties involved and the communities we serve across Florida," Chief Legal Officer Danielle Gray remarked.

    For this year Walgreens Boots Boots's revenue will be around 1.06 billion USD. This is according to the average of the analysts' estimates. This is hugely lower than 2022's revenue of 1.26 billion USD.

    Historical revenues and results Walgreens Boots Boots plus estimates 2023

    aandelenkoers

    Walgreens Boots Boots Ann Arbor ©

    Walgreens Boots
    Walgreens Boots


    The analysts expect for 2023 a net profit of 105 million USD. According to most of the analysts the company will have a profit per share for this book year of 3.03 USD. So the price/earnings-ratio equals 31.59.

    Analysts expect a dividend of 2.52 USD per share. Thus the dividend yield equals 2.63 percent. The average dividend yield of the financial companies equals an attractive 3.55 percent.

    Walgreens Boots Boots's market capitalization is based on the number of outstanding shares around 3.07 billion USD.

    On Friday the stock closed at 95.73 USD.

    Historical stock prices Walgreens Boots Boots

    stock price walgreensboots

    ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
    news@valuespectrum.com

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.